ARTICLE | Management Tracks
Lalezari named interim CEO at CytoDyn
Plus: Sutro promotes Chung to president and COO, and updates from Madrigal, MediWound, Diakonos and Acadia
November 22, 2023 10:12 PM UTC
CytoDyn Inc. (OTCQX:CYDY) named Jacob Lalezari interim CEO, and said that CFO Antonio Migliarese would relinquish the role of interim president that he has held since May. Lalezari served as CytoDyn’s interim CMO in 2020 and has been on the company’s scientific advisory board for several years. The company is developing leronlimab, a humanized IgG4 mAb to treat infectious disease, cancer, and autoimmune conditions.
Antibody-drug conjugate company Sutro Biopharma Inc. (NASDAQ:STRO) promoted Jane Chung from chief commercial officer (CCO) to president and COO, effective Dec. 1. Chung was president of AstraZeneca plc (LSE:AZN; NASDAQ:AZN) in Canada before she joined Sutro in 2021. ...